- Home
- HOWL vs TLSA Comparison
HOWL vs TLSA Comparison
Compare HOWL & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- TLSA
- Stock Information
- Founded
- HOWL 2017
- TLSA 2013
- Country
- HOWL United States
- TLSA United Kingdom
- Employees
- HOWL N/A
- TLSA N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- HOWL Health Care
- TLSA Health Care
- Exchange
- HOWL Nasdaq
- TLSA Nasdaq
- Market Cap
- HOWL 53.4M
- TLSA 187.0M
- IPO Year
- HOWL 2021
- TLSA 2000
- Fundamental
- Price
- HOWL $1.25
- TLSA $1.45
- Analyst Decision
- HOWL Strong Buy
- TLSA
- Analyst Count
- HOWL 3
- TLSA 0
- Target Price
- HOWL $8.33
- TLSA N/A
- AVG Volume (30 Days)
- HOWL 549.8K
- TLSA 247.0K
- Earning Date
- HOWL 08-07-2025
- TLSA 07-22-2025
- Dividend Yield
- HOWL N/A
- TLSA N/A
- EPS Growth
- HOWL N/A
- TLSA N/A
- EPS
- HOWL N/A
- TLSA N/A
- Revenue
- HOWL $1,143,000.00
- TLSA N/A
- Revenue This Year
- HOWL N/A
- TLSA N/A
- Revenue Next Year
- HOWL N/A
- TLSA N/A
- P/E Ratio
- HOWL N/A
- TLSA N/A
- Revenue Growth
- HOWL N/A
- TLSA N/A
- 52 Week Low
- HOWL $0.60
- TLSA $0.63
- 52 Week High
- HOWL $4.18
- TLSA $1.91
- Technical
- Relative Strength Index (RSI)
- HOWL 45.36
- TLSA 48.43
- Support Level
- HOWL $1.03
- TLSA $1.43
- Resistance Level
- HOWL $1.10
- TLSA $1.81
- Average True Range (ATR)
- HOWL 0.07
- TLSA 0.09
- MACD
- HOWL -0.02
- TLSA -0.02
- Stochastic Oscillator
- HOWL 22.81
- TLSA 18.53
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.